Publications

Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

HPV-Targeted

TitleDisease TargetProduct
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Science Translational Medicine — October 2012
Cervical DysplasiaVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Molecular Therapy Oncolytics — January 2016
Cervical DysplasiaVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Clinical Cancer Research — January 2018
Cervical DysplasiaVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis
BMJ — July 2016
Cervical DysplasiaVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
Vaccines — January 2020
RRPINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Clinical Cancer Research — January 2019
Head & Neck CancerMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet — September 2015
Cervical DysplasiaVGX-3100